Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Exatecan is a derivative of camptothecin (Item No. 11694) and DNA topoisomerase I inhibitor (IC50 = 0.975 µg/ml).1 It inhibits cell growth in a panel of 32 breast, colon, stomach, and lung cancer cell lines (GI50s = 0.125-10.4 ng/ml). Exatecan (3.325-50 mg/kg) reduces tumor growth in an SC-6-JCK gastric adenocarcinoma mouse xenograft model. It reduces tumor weight in HCT116, PC-6, and PC12 mouse xenograft models when administered at a dose of 75 mg/kg.2 Exatecan has also been used in the synthesis of cytotoxic payload moieties of antibody-drug conjugates (ADCs).3 Formulations containing exatecan have been used in the treatment of breast, gastric, and gastroesophageal cancers.
WARNING This product is not for human or veterinary use.
1. A new water-
2. DE-
3. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-